Amyloid precursor protein (APP) is broken down by beta-secretase (BACE), a transmembrane aspartic proteinase, to produce the soluble ectodomain (sAPPbeta) and its C-terminal fragment (CTFbeta). Therapeutics for Alzheimer's disease (AD) frequently target BACE. The enzyme comes in two different varieties: BACE1 and BACE2.
The hallmark neuropathology of Alzheimer's disease (AD) is the deposition of amyloid-protein (A) to produce neuritic plaques. By cleavages caused by - and -secretases, A is produced from APP. The -secretase BACE1 causes severe side effects when inhibited, whereas BACE2 suppresses A normally by cleaving APP/A at the -site (Phe20) in the A domain.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2701 | AZD3293 (Lanabecestat) | 1383982-64-6 | Lanabecestat (formerly AZD-3293; LY-3314814; AZD3293; LY3314814) is a novel potent, orally bioactive, highly permeable,brain-penetreable inhibitor of beta-secretase 1 cleaving enzyme (BACE) with aKiof 0.4 nM. |
|
V1314 | AZD3839 | 1227163-84-9 | AZD3839 (AZD-3839; AZD 3839) is a novel, potent and selective BACE1 (β-secretase) inhibitor with the potential for the treatment of Alzheimer disease. |
|
V1312 | LY2886721 | 1262036-50-9 | LY2886721 (LY 2886721; LY-2886721) is a novel, potent and selective BACE (β-secretase) inhibitor with the potential for the treatment of AD-Alzheimers Disease. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
